Navigation Links
NuVasive Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/25/2009

d surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation. NuVasive's Biologic product portfolio includes FormaGraft(R), Osteocel Plus(R), and the Progentix(R) products, all of which are intended to facilitate fusion and complement the core fixation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the risk that the Company may not be successful in integrating acquired technology or products, such as the Progentix family of products; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that the Company's revenue or profitability projections may prove incorrect because of unexpected difficulty in generating sales or achieving anticipated profitability; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases a
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
2. NuVasive to Present at Canaccord Adams Musculoskeletal Conference
3. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
4. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
5. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
6. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
7. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
8. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
9. NuVasive Acquires First Stem Cell Bone Graft Substitute
10. NuVasive Reports First Quarter 2008 Financial Results
11. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... It is better to give than to receive at ... new study suggests. , The study found that 15- and ... their money to family members, are less likely to become ... risks or keeping the money for themselves. , The researchers ... Academy of Sciences . , The study focused on the ...
(Date:4/24/2014)... first flu pandemic in the 21st century. The virus ... 50 people in the country. Since 2011 the pH1N1 ... , Infections with influenza pH1N1 virus vary from ... recommended Tamiflu for treatment of patients with severe or ... it targets viral proteins which mutate quickly and the ...
(Date:4/23/2014)... clinical trials for a new experimental drug to ... Patients treated with CPX-351, a combination of the ... responses than patients treated with the standard drug ... is an aggressive blood cancer with very low ... explained Jeffrey Lancet, M.D., senior member of the ...
(Date:4/23/2014)... high-energy particles, simulating conditions astronauts would face on a ... slower reaction times, even when the radiation exposure is ... which affected a large subset, but far from ... to protein changes in the brain, the scientists say. ... suggest it may be possible to develop a biological ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3
... Satori World Medical, ... certain providers of Sistemas Medicos Nacionales, S.A. de C.V. (SIMNSA) to its network in Mexico. ... San Diego, CA ... in the emerging medical tourism industry, announced the addition of certain providers of Sistemas Medicos ...
... 14 Continuing its efforts to educate, inform, and ... not-for-profit patient-focused organization, is hosting its 25-minute live call-in ... on Monday, October 19, 2009 at 6:00 PM on ... a frank discussion regarding Retail Health Clinics with Erin ...
... HARBIN, China, Oct. 14 /PRNewswire-Asia-FirstCall/-- SOKO Fitness ... of fitness centers,and beauty salons and spas in Northeast China, ... Officer Yu Xia, and,Corporate Secretary Jiang Judy will host a ... 9 am EDT on Oct. 16. , , ...
... of altruism , WEDNESDAY, Oct. 14 (HealthDay News) ... they,re not likely to offer help voluntarily, say researchers ... Japanese research team studied six pairs of chimpanzees (three ... designed to find out whether a chimpanzee would give ...
... ... feature the latest developments in its advanced DuraHeart™ Left-Ventricular Assist System at the 23rd ... , ... Arbor, Mich. (PRWEB) -- Terumo Heart, Inc., a wholly owned subsidiary of Terumo Corporation, ...
... BNVI ) announced today the appointment of Dr. Debu ... Program at the University Southern California, to the company,s Medical ... researcher in the area of breast cancer. , "We ... in the area of breast cancer join our Medical Advisory ...
Cached Medicine News:Health News:SIMNSA is added to the Satori Global Network™ in Mexico to Offer U.S. Employers Cross Border Health Benefit Options 2Health News:Retail Health Clinics - The Real Story 2Health News:SOKO Fitness & Spa Group, Inc. to Hold FY 2010 Q1 Earnings Call on Oct. 16 2Health News:SOKO Fitness & Spa Group, Inc. to Hold FY 2010 Q1 Earnings Call on Oct. 16 3Health News:If You Want Help From a Chimp, You'll Have to Ask 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 2Health News:DuraHeart™ Third-Generation Left Ventricular Assist System Featured at 23rd Annual Meeting of the European Association for Cardio-thoracic Surgery 3Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 2Health News:Bionovo Adds Dr. Debu Tripathy to Their Medical Advisory Board 3
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , , , ... Claims and Clearinghouse Service in the 2009 Top 20 ... RealMed is a dynamic revenue cycle management solution providing advanced, ... payers. KLAS is an independent research firm specializing in ...
... ... today announced a series of flexible financing solutions ... and meet deadlines defined within the HITECH provision of the ... interest terms for qualified customers, the solutions enable organizations to ...
Cached Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4
The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
... Anti-HCV Low Titer Performance Panel consists of ... to strong positive for antibodies to the ... for use by manufacturers and diagnostic laboratories ... from all major test systems are included ...
Comprised of a monofilament polypropylene mesh coated with hydrophilic porcine collagen, Pelvitex™ mesh is clinically proven coating to enhance the healing process, along with the strength and d...
... a biological material derived from ... for excellent suppleness and strength. ... ensure high levels of quality ... enhances the biocompatibility, performance and ...
Medicine Products: